- Home
- MIRM vs PAYO Comparison
MIRM vs PAYO Comparison
Compare MIRM & PAYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- PAYO
- Stock Information
- Founded
- MIRM 2018
- PAYO 2005
- Country
- MIRM United States
- PAYO United States
- Employees
- MIRM N/A
- PAYO N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- PAYO EDP Services
- Sector
- MIRM Health Care
- PAYO Technology
- Exchange
- MIRM Nasdaq
- PAYO Nasdaq
- Market Cap
- MIRM 1.9B
- PAYO 2.2B
- IPO Year
- MIRM 2019
- PAYO N/A
- Fundamental
- Price
- MIRM $39.10
- PAYO $6.36
- Analyst Decision
- MIRM Strong Buy
- PAYO Strong Buy
- Analyst Count
- MIRM 11
- PAYO 7
- Target Price
- MIRM $58.55
- PAYO $12.36
- AVG Volume (30 Days)
- MIRM 476.2K
- PAYO 4.1M
- Earning Date
- MIRM 05-07-2025
- PAYO 05-07-2025
- Dividend Yield
- MIRM N/A
- PAYO N/A
- EPS Growth
- MIRM N/A
- PAYO 29.17
- EPS
- MIRM N/A
- PAYO 0.31
- Revenue
- MIRM $336,888,000.00
- PAYO $977,716,000.00
- Revenue This Year
- MIRM $29.51
- PAYO $9.03
- Revenue Next Year
- MIRM $20.27
- PAYO $10.79
- P/E Ratio
- MIRM N/A
- PAYO $20.52
- Revenue Growth
- MIRM 80.76
- PAYO 17.64
- 52 Week Low
- MIRM $23.14
- PAYO $4.73
- 52 Week High
- MIRM $54.23
- PAYO $11.29
- Technical
- Relative Strength Index (RSI)
- MIRM 34.64
- PAYO 36.85
- Support Level
- MIRM $37.83
- PAYO $5.71
- Resistance Level
- MIRM $40.32
- PAYO $6.55
- Average True Range (ATR)
- MIRM 2.47
- PAYO 0.40
- MACD
- MIRM -0.33
- PAYO 0.04
- Stochastic Oscillator
- MIRM 25.14
- PAYO 35.14
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.